

Joao Goncalves

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2991423/publications.pdf>

Version: 2024-02-01

141
papers

5,163
citations

101543

36
h-index

102487

66
g-index

149
all docs

149
docs citations

149
times ranked

7159
citing authors

#	ARTICLE	IF	CITATIONS
1	A de novo paradigm for male infertility. <i>Nature Communications</i> , 2022, 13, 154.	12.8	38
2	Screening polymeric ionic liquids for chromatography-based purification of bacteriophage M13. <i>Separation and Purification Technology</i> , 2021, 257, 117906.	7.9	2
3	Systematic Review and Principal Components Analysis of the Immunogenicity of Adalimumab. <i>BioDrugs</i> , 2021, 35, 35-45.	4.6	2
4	Immunogenicity of biologic agents in rheumatology. <i>Nature Reviews Rheumatology</i> , 2021, 17, 81-97.	8.0	43
5	Anti-HIV-1 Activity of pepRF1, a Proteolysis-Resistant CXCR4 Antagonist Derived from Dengue Virus Capsid Protein. <i>ACS Infectious Diseases</i> , 2021, 7, 6-22.	3.8	3
6	Integrated in Silico and Experimental Approach towards the Design of a Novel Recombinant Protein Containing an Anti-HER2 scFv. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3547.	4.1	10
7	A purification platform for antibodies and derived fragments using a de novo designed affinity adsorbent. <i>Separation and Purification Technology</i> , 2021, 265, 118476.	7.9	5
8	Methods and cell-based strategies to produce antibody libraries: current state. <i>Applied Microbiology and Biotechnology</i> , 2021, 105, 7215-7224.	3.6	1
9	APOBEC3B Potently Restricts HIV-2 but Not HIV-1 in a Vif-Dependent Manner. <i>Journal of Virology</i> , 2021, 95, e0117021.	3.4	3
10	Origin, phylogeny, variability and epitope conservation of SARS-CoV-2 worldwide. <i>Virus Research</i> , 2021, 304, 198526.	2.2	5
11	Biosimilars in an era of rising oncology treatment options. <i>Future Oncology</i> , 2021, 17, 3881-3892.	2.4	5
12	Evaluation of Male Fertility-Associated Loci in a European Population of Patients with Severe Spermatogenic Impairment. <i>Journal of Personalized Medicine</i> , 2021, 11, 22.	2.5	10
13	Highly Specific Blood-Brain Barrier Transmigrating Single-Domain Antibodies Selected by an In Vivo Phage Display Screening. <i>Pharmaceutics</i> , 2021, 13, 1598.	4.5	10
14	Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience. <i>Journal of Dermatological Treatment</i> , 2020, 31, 794-800.	2.2	26
15	Inhibition of HIV replication through siRNA carried by CXCR4-targeted chimeric nanobody. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 2859-2870.	5.4	14
16	Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents. <i>BioDrugs</i> , 2020, 34, 27-37.	4.6	35
17	Understanding and Minimising Injection-Site Pain Following Subcutaneous Administration of Biologics: A Narrative Review. <i>Rheumatology and Therapy</i> , 2020, 7, 741-757.	2.3	37
18	Protein Delivery of Cell-Penetrating Zinc-Finger Activators Stimulates Latent HIV-1-Infected Cells. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 18, 145-158.	4.1	3

#	ARTICLE	IF	CITATIONS
19	Biologic Drug Quality Assurance to Optimize HER2+ Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3. Targeted Oncology, 2020, 15, 467-475.	3.6	11
20	The NEMP family supports metazoan fertility and nuclear envelope stiffness. Science Advances, 2020, 6, eabb4591.	10.3	11
21	Celastrol Efficacy by Oral Administration in the Adjuvant-Induced Arthritis Model. Frontiers in Medicine, 2020, 7, 455.	2.6	10
22	Magnetic Precipitation: A New Platform for Protein Purification. Biotechnology Journal, 2020, 15, 2000151.	3.5	5
23	Synthetic antibody discovery against native antigens by CRISPR/Cas9-library generation and endoplasmic reticulum screening. Applied Microbiology and Biotechnology, 2020, 104, 2501-2512.	3.6	3
24	LUZP1 and the tumor suppressor EPLIN modulate actin stability to restrict primary cilia formation. Journal of Cell Biology, 2020, 219, .	5.2	25
25	P664 SB5 and reference adalimumab show cross-immunogenicity in patients with inflammatory bowel disease or rheumatoid arthritis. Journal of Crohn's and Colitis, 2019, 13, S451-S452.	1.3	0
26	Nucleolin-based targeting strategies for cancer therapy: from targeted drug delivery to cytotoxic ligands. Drug Discovery Today, 2019, 24, 1985-2001.	6.4	52
27	Biosimilars: An Opportunity to Update the Product Information of Biological Drugs Regarding their Immunogenicity. BioDrugs, 2019, 33, 693-695.	4.6	0
28	Biosimilars in rheumatology. Pharmacological Research, 2019, 149, 104467.	7.1	8
29	Analysis of Immunogenicity Data in the Product Information of Biological Drugs: A Need to Report Immunogenicity Data Systematically. BioDrugs, 2019, 33, 683-691.	4.6	5
30	Era of biosimilars in rheumatology: reshaping the healthcare environment. RMD Open, 2019, 5, e000900.	3.8	67
31	Spatial and proteomic profiling reveals centrosome-independent features of centriolar satellites. EMBO Journal, 2019, 38, e101109.	7.8	73
32	Cilia Distal Domain: Diversity in Evolutionarily Conserved Structures. Cells, 2019, 8, 160.	4.1	34
33	Insights on the Formulation of Recombinant Proteins. Advances in Biochemical Engineering/Biotechnology, 2019, 171, 23-54.	1.1	3
34	Therapeutic Antibody Engineering and Selection Strategies. Advances in Biochemical Engineering/Biotechnology, 2019, 171, 55-86.	1.1	19
35	SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481989108.	3.2	11
36	Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Annals of the Rheumatic Diseases, 2018, 77, 165-174.	0.9	173

#	ARTICLE	IF	CITATIONS
37	M13 bacteriophage purification using poly(ionic liquids) as alternative separation matrices. Journal of Chromatography A, 2018, 1532, 246-250.	3.7	10
38	AB0473â€¦Immunogenicity of biosimilars for rheumatic diseases: an updated review from regulatory documents and confirmatory clinical trials. , 2018, , .		0
39	Establishment of a bioluminescent canine B-cell lymphoma xenograft model for monitoring tumor progression and treatment response in preclinical studies. PLoS ONE, 2018, 13, e0208147.	2.5	6
40	Chimeric Small Antibody Fragments as Strategy to Deliver Therapeutic Payloads. Advances in Protein Chemistry and Structural Biology, 2018, 112, 143-182.	2.3	11
41	Global Interactomics Uncovers Extensive Organellar Targeting by Zika Virus. Molecular and Cellular Proteomics, 2018, 17, 2242-2255.	3.8	112
42	Anticancer activity and antibody-dependent cell-mediated cytotoxicity of novel anti-nucleolin antibodies. Scientific Reports, 2018, 8, 7450.	3.3	12
43	Editorial: antigenic response to <scp>CT</scp>â€P13 and infliximab originator in <scp>IBD</scp> shows similar epitope recognitionâ€”evidence from basic science supports safe switching to biosimilars. Authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2018, 48, 575-576.	3.7	0
44	Antigenic response to <scp>CT</scp>â€P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition. Alimentary Pharmacology and Therapeutics, 2018, 48, 507-522.	3.7	20
45	The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma. Oncotarget, 2018, 9, 28586-28598.	1.8	24
46	FRI0663â€¦The fine specificity of anti-drug antibody responses to originator and biosimilar infliximab: analyses across five diseases from the 52-week randomized nor-switch study. , 2018, , .		0
47	SAT0160â€¦Immunogenicity of biosimilars for the treatment of inflammatory rheumatic diseases: a review from confirmatory clinical trials. , 2017, , .		0
48	SAT0046â€¦TNF antagonist drug safety assessment by pharmacovigilance signaling and post-marketing adverse event reports. , 2017, , .		0
49	Modular Assembly of Reversible Multivalent Cancerâ€Cellâ€Targeting Drug Conjugates. Angewandte Chemie - International Edition, 2017, 56, 9346-9350.	13.8	29
50	Albumin-binding domain from Streptococcus zooepidemicus protein Zag as a novel strategy to improve the half-life of therapeutic proteins. Journal of Biotechnology, 2017, 253, 23-33.	3.8	14
51	Modular Assembly of Reversible Multivalent Cancerâ€Cellâ€Targeting Drug Conjugates. Angewandte Chemie, 2017, 129, 9474-9478.	2.0	6
52	Quantitative analysis of molecular partition towards lipid membranes using surface plasmon resonance. Scientific Reports, 2017, 7, 45647.	3.3	36
53	Interactions Between Therapeutic Proteins and Small Molecules: The Shared Role of Perpetrators and Victims. Clinical Pharmacology and Therapeutics, 2017, 102, 649-661.	4.7	6
54	mi<scp>RNA</scp> profiling of human naive <scp>CD</scp>4 T cells links miRâ€34câ€5p to cell activation and <scp>HIV</scp> replication. EMBO Journal, 2017, 36, 346-360.	7.8	32

#	ARTICLE	IF	CITATIONS
55	Widening the spectrum of deletions and molecular mechanisms underlying alpha-thalassemia. <i>Annals of Hematology</i> , 2017, 96, 1921-1929.	1.8	6
56	Characterization of plasma labile heme in hemolytic conditions. <i>FEBS Journal</i> , 2017, 284, 3278-3301.	4.7	55
57	<i>Tetrahymena</i> Cilia Cap is Built in a Multi-step Process: A Study by Atomic Force Microscopy. <i>Protist</i> , 2017, 168, 697-717.	1.5	4
58	Position Paper from the Portuguese Association of Hospital Pharmacists for biosimilar therapeutic antibodies. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017, 42, 239-243.	1.5	4
59	Considering biosimilar policy. <i>Considerations in Medicine</i> , 2017, 1, 19-24.	0.0	0
60	Biosimilars already approved and in development. <i>Considerations in Medicine</i> , 2017, 1, 7-12.	0.0	6
61	The biosimilar approval process: how different is it?. <i>Considerations in Medicine</i> , 2017, 1, 3-6.	0.0	25
62	Biosimilars: considerations for clinical practice. <i>Considerations in Medicine</i> , 2017, 1, 13-18.	0.0	18
63	The Ciliary Transition Zone: Finding the Pieces and Assembling the Gate. <i>Molecules and Cells</i> , 2017, 40, 243-253.	2.6	145
64	AB0096â€¦Efficacy and safety of oral administration of pure celastrol in aia rats. , 2017, , .		7
65	The changing landscape of biosimilars in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 974-982.	0.9	160
66	Development of synthetic light-chain antibodies as novel and potent HIV fusion inhibitors. <i>Aids</i> , 2016, 30, 1691-1701.	2.2	12
67	Next-generation sequencing of hereditary hemochromatosis-related genes: Novel likely pathogenic variants found in the Portuguese population. <i>Blood Cells, Molecules, and Diseases</i> , 2016, 61, 10-15.	1.4	12
68	CIB1 and CIB2 are HIV-1 helper factors involved in viral entry. <i>Scientific Reports</i> , 2016, 6, 30927.	3.3	11
69	Pharmacoeconomics of Biosimilars: What Is There to Gain from Them?. <i>Current Rheumatology Reports</i> , 2016, 18, 50.	4.7	27
70	Camphor-based CCR5 blocker lead compounds â€“ a computational and experimental approach. <i>RSC Advances</i> , 2016, 6, 56249-56259.	3.6	4
71	A novel reactive epitope-based antigen targeted by serum autoantibodies in oligoarticular and polyarticular juvenile idiopathic arthritis and development of an electrochemical biosensor. <i>Immunobiology</i> , 2016, 221, 634-640.	1.9	10
72	Biosimilar DMARDs: What Does the Future Hold?. <i>Drugs</i> , 2016, 76, 629-637.	10.9	11

#	ARTICLE	IF	CITATIONS
73	Reactivation of Latent HIV-1 Expression by Engineered TALE Transcription Factors. <i>PLoS ONE</i> , 2016, 11, e0150037.	2.5	10
74	Biosimilar monoclonal antibodies: preclinical and clinical development aspects. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 698-705.	0.8	11
75	Improved serological detection of rheumatoid arthritis: a highly antigenic mimotope of carbonic anhydrase III selected in a murine model by phage display. <i>Arthritis Research and Therapy</i> , 2015, 17, 168.	3.5	11
76	Rare double sex and mab-3-related transcription factor 1 regulatory variants in severe spermatogenic failure. <i>Andrology</i> , 2015, 3, 825-833.	3.5	17
77	A Dynamic Protein Interaction Landscape of the Human Centrosome-Cilium Interface. <i>Cell</i> , 2015, 163, 1484-1499.	28.9	446
78	Anti-type II collagen antibodies detection and avidity in patients with oligoarticular and polyarticular forms of juvenile idiopathic arthritis. <i>Immunology Letters</i> , 2015, 165, 20-25.	2.5	9
79	The Mutational Spectrum of <i>WT1</i> in Male Infertility. <i>Journal of Urology</i> , 2015, 193, 1709-1715.	0.4	11
80	The hepcidin gene promoter nc-1010C & T; $\hat{\sim}$ 582A & G haplotype modulates serum ferritin in individuals carrying the common H63D mutation in HFE gene. <i>Annals of Hematology</i> , 2014, 93, 2063-2066.	1.8	3
81	Biodistribution of a ⁶⁷ Ga-labeled anti-TNF VHH single-domain antibody containing a bacterial albumin-binding domain (Zag). <i>Nuclear Medicine and Biology</i> , 2014, 41, e44-e48.	0.6	16
82	Mitochondrial thioredoxin reductase inhibition, selenium status, and Nrf-2 activation are determinant factors modulating the toxicity of mercury compounds. <i>Free Radical Biology and Medicine</i> , 2014, 73, 95-105.	2.9	85
83	A novel Alu-mediated microdeletion at 11p13 removes <i>WT1</i> in a patient with cryptorchidism and azoospermia. <i>Reproductive BioMedicine Online</i> , 2014, 29, 388-391.	2.4	18
84	<i>Besnoitia besnoiti</i> and <i>Toxoplasma gondii</i> : two apicomplexan strategies to manipulate the host cell centrosome and Golgi apparatus. <i>Parasitology</i> , 2014, 141, 1436-1454.	1.5	9
85	Pharmacology of biosimilar candidate drugs in rheumatology: a literature review. <i>Acta Reumatol³gica Portuguesa</i> , 2014, 39, 19-26.	0.2	8
86	The Portuguese Society of Rheumatology position paper on the use of biosimilars. <i>Acta Reumatol³gica Portuguesa</i> , 2014, 39, 60-71.	0.2	20
87	Autoinhibition of TBCB regulates EB1-mediated microtubule dynamics. <i>Cellular and Molecular Life Sciences</i> , 2013, 70, 357-371.	5.4	20
88	Host Factors and HIV-1 Replication: Clinical Evidence and Potential Therapeutic Approaches. <i>Frontiers in Immunology</i> , 2013, 4, 343.	4.8	45
89	Human Spermatogenic Failure Purges Deleterious Mutation Load from the Autosomes and Both Sex Chromosomes, including the Gene <i>DMRT1</i> . <i>PLoS Genetics</i> , 2013, 9, e1003349.	3.5	118
90	<i>Mob1</i> : defining cell polarity for proper cell division. <i>Journal of Cell Science</i> , 2012, 125, 516-527.	2.0	34

#	ARTICLE	IF	CITATIONS
91	Recombinant rabbit single-chain antibodies bind to the catalytic and C-terminal domains of HIV-1 integrase protein and strongly inhibit HIV-1 replication. <i>Biotechnology and Applied Biochemistry</i> , 2012, 59, 353-366.	3.1	11
92	The Expression of Tubulin Cofactor A (TBCA) Is Regulated by a Noncoding Antisense TbcA RNA during Testis Maturation. <i>PLoS ONE</i> , 2012, 7, e42536.	2.5	29
93	Assessing combinatorial strategies to multimerize libraries of single-domain antibodies. <i>Biotechnology and Applied Biochemistry</i> , 2012, 59, 193-204.	3.1	3
94	Is prnt a Pseudogene? Identification of Ram Prt in Testis and Ejaculated Spermatozoa. <i>PLoS ONE</i> , 2012, 7, e42957.	2.5	16
95	Sulfated Polysaccharides in Marine Sponges: Extraction Methods and Anti-HIV Activity. <i>Marine Drugs</i> , 2011, 9, 139-153.	4.6	35
96	HIV-1 Vif Interaction with APOBEC3 Deaminases and its Characterization by a New Sensitive Assay. <i>Journal of NeuroImmune Pharmacology</i> , 2011, 6, 296-307.	4.1	5
97	Identification of SOX3 as an XX male sex reversal gene in mice and humans. <i>Journal of Clinical Investigation</i> , 2011, 121, 328-341.	8.2	234
98	TBCCD1, a new centrosomal protein, is required for centrosome and Golgi apparatus positioning. <i>EMBO Reports</i> , 2010, 11, 194-200.	4.5	50
99	Novel HIV-1 Knockdown Targets Identified by an Enriched Kinases/Phosphatases shRNA Library Using a Long-Term Iterative Screen in Jurkat T-Cells. <i>PLoS ONE</i> , 2010, 5, e9276.	2.5	31
100	Intrabody-based Mapping of Latency-associated Nuclear Antigen from Kaposi's Sarcoma-associated Herpesvirus Show Conserved Epitopes for Viral Latency Inhibition. <i>Virology: Research and Treatment</i> , 2010, 2, VRT.S975.	3.5	0
101	Towards Inhibition of Vif-APOBEC3G Interaction: Which Protein to Target?. <i>Advances in Virology</i> , 2010, 2010, 1-10.	1.1	6
102	The AZFc region of the Y chromosome: at the crossroads between genetic diversity and male infertility. <i>Human Reproduction Update</i> , 2010, 16, 525-542.	10.8	122
103	Genetic Dissection of the AZF Regions of the Human Y Chromosome: Thriller or Filler for Male (In)fertility?. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-18.	3.0	74
104	Revisiting the tubulin folding pathway: new roles in centrosomes and cilia. <i>Biomolecular Concepts</i> , 2010, 1, 423-434.	2.2	10
105	Incorrect DNA methylation of the DAZL promoter CpG island associates with defective human sperm. <i>Human Reproduction</i> , 2010, 25, 2647-2654.	0.9	135
106	Ubiquitin-fusion as a strategy to modulate protein half-life: A3G antiviral activity revisited. <i>Virology</i> , 2009, 393, 286-294.	2.4	2
107	Recombinant Antibodies as Therapeutic Agents. <i>BioDrugs</i> , 2008, 22, 301-314.	4.6	57
108	Mutation C11994T in the mitochondrial ND4 gene is not a cause of low sperm motility in Portugal. <i>Fertility and Sterility</i> , 2008, 89, 738-741.	1.0	25

#	ARTICLE	IF	CITATIONS
109	KSHV Latency in Transformed B-cells: The Role of LANA1 as a Therapeutic Target. <i>Virology: Research and Treatment</i> , 2008, 1, VRT.S631.	3.5	1
110	No Evidence for an mtDNA Role in Sperm Motility: Data from Complete Sequencing of Asthenozoospermic Males. <i>Molecular Biology and Evolution</i> , 2007, 24, 868-874.	8.9	60
111	HIV-1 Vif protein blocks the cytidine deaminase activity of B-cell specific AID in <i>E. coli</i> by a similar mechanism of action. <i>Molecular Immunology</i> , 2007, 44, 583-590.	2.2	22
112	Piezoelectric biosensors for biorecognition analysis: Application to the kinetic study of HIV-1 Vif protein binding to recombinant antibodies. <i>Journal of Biotechnology</i> , 2007, 132, 142-148.	3.8	25
113	Recombinant single-chain variable fragment and single domain antibody piezoimmunosensors for detection of HIV1 virion infectivity factor. <i>Biosensors and Bioelectronics</i> , 2007, 23, 384-392.	10.1	18
114	Characterizing partial AZFc deletions of the Y chromosome with amplicon-specific sequence markers. <i>BMC Genomics</i> , 2007, 8, 342.	2.8	30
115	Molecular construction of bionanoparticles: chimaeric SIV p17/HIV I p6 nanoparticles with minimal viral protein content. <i>Biotechnology and Applied Biochemistry</i> , 2007, 48, 35.	3.1	6
116	Inhibition of Human Immunodeficiency Virus Type 1 Replication with Artificial Transcription Factors Targeting the Highly Conserved Primer-Binding Site. <i>Journal of Virology</i> , 2006, 80, 2873-2883.	3.4	49
117	Intrabodies targeting the Kaposi sarcoma-associated herpesvirus latency antigen inhibit viral persistence in lymphoma cells. <i>Blood</i> , 2005, 106, 3797-3802.	1.4	34
118	Human mtDNA haplogroups and reduced male fertility: real association or hidden population substructuring. <i>Journal of Developmental and Physical Disabilities</i> , 2005, 28, 241-247.	3.6	29
119	HIV-1 Vif Can Directly Inhibit Apolipoprotein B mRNA-editing Enzyme Catalytic Polypeptide-like 3G-mediated Cytidine Deamination by Using a Single Amino Acid Interaction and Without Protein Degradation. <i>Journal of Biological Chemistry</i> , 2005, 280, 8765-8775.	3.4	78
120	Functional Analysis of Vif Protein Shows Less Restriction of Human Immunodeficiency Virus Type 2 by APOBEC3G. <i>Journal of Virology</i> , 2005, 79, 823-833.	3.4	46
121	Modulation of translation factor's gene expression by histone deacetylase inhibitors in breast cancer cells. <i>Clinical Chemistry and Laboratory Medicine</i> , 2005, 43, 151-6.	2.3	9
122	Cell Type-Specific Targeting with Sindbis Pseudotyped Lentiviral Vectors Displaying Anti-CCR5 Single-Chain Antibodies. <i>Human Gene Therapy</i> , 2005, 16, 223-234.	2.7	32
123	Tubulin cofactor A gene silencing in mammalian cells induces changes in microtubule cytoskeleton, cell cycle arrest and cell death. <i>FEBS Letters</i> , 2005, 579, 3515-3524.	2.8	42
124	Cell-based Assay for Testing Susceptibility of HIV-1 to Protease Inhibitors. <i>Retrovirology</i> , 2005, 2, P140.	2.0	0
125	Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. <i>Genes and Development</i> , 2004, 18, 2861-2866.	5.9	259
126	Attenuation of HIV-1 Replication in Primary Human Cells with a Designed Zinc Finger Transcription Factor. <i>Journal of Biological Chemistry</i> , 2004, 279, 14509-14519.	3.4	77

#	ARTICLE	IF	CITATIONS
127	HIV-1 Vif and APOBEC3G: multiple roads to one goal. <i>Retrovirology</i> , 2004, 1, 28.	2.0	26
128	Camelized Rabbit-derived VH Single-domain Intrabodies Against Vif Strongly Neutralize HIV-1 Infectivity. <i>Journal of Mathematical Analysis and Applications</i> , 2004, 294, 525-525.	1.0	0
129	Camelized Rabbit-derived VH Single-domain Intrabodies Against Vif Strongly Neutralize HIV-1 Infectivity. <i>Journal of Molecular Biology</i> , 2004, 340, 525-542.	4.2	81
130	Catechols from abietic acid. <i>Bioorganic and Medicinal Chemistry</i> , 2003, 11, 1631-1638.	3.0	76
131	Functional Neutralization of HIV-1 Vif Protein by Intracellular Immunization Inhibits Reverse Transcription and Viral Replication. <i>Journal of Biological Chemistry</i> , 2002, 277, 32036-32045.	3.4	68
132	High frequency of DAZ1/DAZ2 gene deletions in patients with severe oligozoospermia. <i>Molecular Human Reproduction</i> , 2002, 8, 286-298.	2.8	153
133	Ultrastructure of HIV-1 Genomic RNA. <i>Virology</i> , 1997, 233, 271-279.	2.4	96
134	Phosphorylation of Vif and Its Role in HIV-1 Replication. <i>Journal of Biological Chemistry</i> , 1996, 271, 10121-10129.	3.4	103
135	Role of Vif in human immunodeficiency virus type 1 reverse transcription. <i>Journal of Virology</i> , 1996, 70, 8701-8709.	3.4	118
136	Î²-Thalassaemia unlinked to the Î²-globin gene interacts with sickle-cell trait in a Portuguese family. <i>British Journal of Haematology</i> , 1995, 91, 85-89.	2.5	20
137	Biological activity of human immunodeficiency virus type 1 Vif requires membrane targeting by C-terminal basic domains. <i>Journal of Virology</i> , 1995, 69, 7196-7204.	3.4	69
138	A novel mosaic Bantu/Benin/Bantu Î²s haplotype found in several African populations. <i>Human Genetics</i> , 1994, 94, 101-103.	3.8	4
139	Subcellular localization of the Vif protein of human immunodeficiency virus type 1. <i>Journal of Virology</i> , 1994, 68, 704-712.	3.4	138
140	Novel promoter and splice junction defects add to the genetic, clinical or geographic heterogeneity of Î²-thalassaemia in the Portuguese population. <i>Human Genetics</i> , 1992, 89, 573-6.	3.8	40
141	Importation route of the sickle cell trait into Portugal: contribution of molecular epidemiology. <i>Human Biology</i> , 1992, 64, 891-901.	0.2	17